A 12-year odyssey of a cancer drug that works in a subcellular organelle: From discovery of a unique and promising tumor target – featured on the cover of the Journal of Clinical Investigation – through startup company, grant-writing, DoD funding, Wall Street disinterest, perseverance, and finally, approval to initiate clinical trials.